Prosonix has announced that Ken Cunningham will replace Jim Philips as Non-executive Chairman. Cunningham, who is also Chair of the company’s scientific advisory board, is a former CEO of Skyepharma. He has been a member of the board of Prosonix since September 2011.
Phillips, who is retiring from the board of directors, said, “After five years chairing Prosonix and helping shape it into the inhalation product-focused company it is today, I am delighted to hand over Chairmanship to Dr. Ken Cunningham to bring his respiratory experience to bear towards the company’s future success.”
Cunningham commented, “Over recent years, Prosonix’s particle engineering technology has repeatedly demonstrated its exciting potential for optimizing many of the respiratory medicines currently used in the treatment of asthma and COPD. During this period, the company has made a successful transition from applying its technology to third party compounds to using it to build its own pipeline of directly substitutable generic and proprietary inhaled drugs based on improved versions of known drugs in simple, cost effective and already approved devices. I would like to take this opportunity, on behalf of the Prosonix Board, to thank Dr Phillips for his important contribution as Chairman during this period of transformation. I am very pleased to continue his work and help Prosonix deliver its corporate and clinical strategy, which is focused on building further value from the Company’s portfolio of inhaled drug candidates.”
Read the Prosonix press release.
